<DOC>
	<DOCNO>NCT01696305</DOCNO>
	<brief_summary>This study randomize , double-blind , active control phase 3 trial patient thyroid disease , undergo total thyroidectomy ( exclude patient patient past history thyroid surgery ) . An eligible patient randomize allocate either test group ( Hyalobarrier ) active-comparator group ( Guardix-SG ) . He/she undergo marshmallow esophagography detect esophageal dysmotility 6 week study intervention follow 12weeks . During study , patient observer primary secondary efficacy evaluation mask . Non-inferiority test device ( Hyalobarrier ) compare reference device ( Guardix-SG ) confirm use primary efficacy outcome , percentage normal esophageal transit .</brief_summary>
	<brief_title>Study Hyalobarrier Evaluate Anti-adhesive Effect Safety Compared Guardix-SG After Thyroidectomy</brief_title>
	<detailed_description />
	<mesh_term>Thyroid Diseases</mesh_term>
	<criteria>Male female 18 79 year age Patients diagnose thyroid disease undergo total thyroidectomy Naive patient thyroid surgery Given write informed consent Childbearing potential female patient give consent contraception study Pregnant breastfeed female patient Abnormal coagulation panel test Clinically abnormal laboratory value Inappropriate general health condition Past current medication history hyperthyroidism Medication aspirin ( antiplatelet ) surgery Current medication anticoagulant Inoperable ( thyroidectomy ) concurrent diseases Concurrent diseases/conditions unable evaluate primary secondary outcome Participating interventional clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Thyroid disease</keyword>
	<keyword>Hyalobarrier</keyword>
	<keyword>Thyroidectomy</keyword>
	<keyword>anti-adhesive effect</keyword>
</DOC>